Immutep Limited (NASDAQ:IMMP) shares traded higher over the last trading session, gaining 8.09% on 05/26/21. The shares fell to a low of $4.52 before closing at $4.81. Intraday shares traded counted 1.25 million, which was 55.04% higher than its 30-day average trading volume of 2.79M. IMMP’s previous close was $4.45 while the outstanding shares total 64.87M. The stock’s Relative Strength Index (RSI) is 69.26, with weekly volatility at 7.57% and ATR at 0.32. The IMMP stock’s 52-week price range has touched low of $1.03 and a $7.95 high.
Investors have identified the Biotechnology company Immutep Limited as an interesting stock but before investments are made there, an in-depth look at its trading activities will have to be conducted. The share is trading with a market value of around $312.04 million, the company now has both obstacles and catalysts that affect them and they came from their mode of operations. With the company affected by events currently, it is a perfect time to analyze the numbers behind the firm in order to come up with a rather realistic picture of what this stock is.
Immutep Limited (IMMP) Fundamentals that are to be considered.
When analyzing a stock, the first fundamental thing to take into account is the balance sheet. How healthy the balance sheet of a company is will determine if the company will be able to carry out all its financial and non-financial obligations and also keep the faith of its investors. In terms of their assets, the company currently has 45.55 million total, with 3.81 million as their total liabilities.
IMMP were able to record -6.61 million as free cash flow during the 08/25/2021 quarter of the year, this saw their quarterly net cash flow reduce by 20.89 million. In cash movements, the company had a total of -6.61 million as operating cash flow.
Is the stock of IMMP attractive?
4 out of 4 analysts covering the stock have rated it a Buy, while 0 have maintained a Hold recommendation on Immutep Limited. 0 analysts has assigned a Sell rating on the IMMP stock. The 12-month mean consensus price target for the company’s shares has been set at $6.99.